President Timothy Mayleben Just Bought Shares In Esperion Therapeutics, Inc. (NASDAQ:ESPR) [Yahoo! Finance News]
Esperion Therapeutics, Inc. (ESPR)
Last esperion therapeutics, inc. earnings: 2/27 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
investor.esperion.com
Company Research
Source: Yahoo! Finance News
President Timothy Mayleben Just Bought Shares In Esperion Therapeutics, Inc. (NASDAQ:ESPR) Potential Esperion Therapeutics, Inc. NASDAQ:ESPR Check out our latest analysis for Esperion Therapeutics Esperion Therapeutics Insider Transactions Over The Last Year Notably, that recent purchase by President Timothy Mayleben was not the only time they bought Esperion Therapeutics shares this year. Earlier in the year, they paid US$35.25 per share in a US$259k purchase. That implies that an insider found the current price of US$37.82 per share to be enticing. That means they have been optimistic about the company in the past, though they may have changed their mind. We do always like to see insider buying, but it is worth noting if those purchases were made at well below today's share price, as the discount to value may have narrowed with the rising price. The good news for Esperion Therapeutics share holders is that an insider was buying at near the current price. Timothy Mayleben was the onl
Show less
Read more
Impact Snapshot
Event Time:
ESPR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ESPR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ESPR alerts
High impacting Esperion Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
ESPR
News
- Esperion to Report First Quarter 2024 Financial Results on May 7 [Yahoo! Finance]Yahoo! Finance
- Esperion to Report First Quarter 2024 Financial Results on May 7GlobeNewswire
- Esperion Therapeutics, Inc. (NASDAQ: ESPR) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $8.00 price target on the stock.MarketBeat
- Esperion Presents Important New Data from CLEAR Outcomes at ACC.24 Highlighting Value of NEXLETOL® (bempedoic acid) Tablets in Diverse Populations Including Women, Hispanics/Latinx and Patients with Obesity [Yahoo! Finance]Yahoo! Finance
- Esperion Presents Important New Data from CLEAR Outcomes at ACC.24 Highlighting Value of NEXLETOL® (bempedoic acid) Tablets in Diverse Populations Including Women, Hispanics/Latinx and Patients with ObesityGlobeNewswire
ESPR
Earnings
- 2/27/24 - Beat
ESPR
Sec Filings
- 4/11/24 - Form DEF
- 4/11/24 - Form ARS
- 3/15/24 - Form 4
- ESPR's page on the SEC website